NEXIEN BIOPHARMA, INC.
NXEN evidence brief
What we can confirm
- Market Cap:
- $7K
What it means
What to watch
Prepared research question
What matters most for NXEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Market Cap
$7K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2025.
Run NEXIEN BIOPHARMA, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NEXIEN BIOPHARMA, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Financials
Frequently asked questions
Who is the CEO of NEXIEN BIOPHARMA, INC.?
Mr. Richard S. Greenberg is the chief executive officer of NEXIEN BIOPHARMA, INC. (NXEN).
Where is NEXIEN BIOPHARMA, INC. headquartered?
NEXIEN BIOPHARMA, INC. (NXEN) is headquartered in Glendale, CO, United States.
What therapeutic areas does NEXIEN BIOPHARMA, INC. focus on?
NEXIEN BIOPHARMA, INC. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.